Record Revenue Growth, AI-Driven Healthcare Innovation, Expanding Proprietary Brand and Targeting $200 Million Revenue By 2029: Cosmos Health Inc
Washingtoner/10326993

CHICAGO - Washingtoner -- Ø  Targeting $200.6 Million Revenue And $44.2 Million Adjusted EBITDA By 2029

Ø  Record Q1 2026 Revenue Growth Of 31% To $17.9 Million

Ø  Expanding U.S. Commercialization Of Cur18®, Fort18®, Liv18®, And Oliv18®

Ø  Advancing AI-Powered Healthcare Innovation And Research Initiatives

Ø  Strengthening Balance Sheet While Reducing Potential Future Dilution

Cosmos Health Inc. (N A S D A Q: COSM) $COSM continues executing on a strategy designed to build a diversified healthcare platform spanning pharmaceuticals, nutraceuticals, telehealth, proprietary consumer healthcare products, and artificial intelligence-driven research and development.

With operations across Europe, North America, and international markets, the company has developed a vertically integrated healthcare ecosystem combining manufacturing, distribution, research, product development, and digital healthcare services. Recent announcements highlight accelerating momentum across multiple business segments while management projects significant growth through 2029.

Financial Guidance Highlights Transformational Growth Potential

One of the most important recent developments for Cosmos Health was the release of long-term financial guidance covering 2026 through 2029.

Management is targeting approximately:

• $200.6 million in revenue
• $71.2 million in gross profit
• $44.2 million in adjusted EBITDA
• $31.0 million in net income
• $62.9 million in cash
• $92.3 million in stockholders' equity

These projections represent substantial growth from current levels and reflect management's confidence in the scalability of its diversified healthcare platform. Revenue is projected to grow from approximately $65.3 million in 2025 to more than $200 million by 2029 as proprietary products become a larger contributor to overall sales and profitability.

Record First Quarter Results Continue Momentum

The company's first quarter 2026 financial results demonstrated that many of these growth initiatives are already gaining traction.

More on Washingtoner

• Mr. Hospital Bed Showcases the Best Hospital Bed and Air Mattress for Bed Sores for 2026
• City of Tacoma Presents Updated Financial Forecast as Next Step in 'Roadmap to Recovery' to Navigate National Economic Pressures
• Tacoma: Full Intersection Closure at E. 11th Street and St. Paul Avenue for One-Day Asphalt Repairs on June 27
• Spokane: Early-Morning House Fire Damages Two Homes on East Sanson Avenue
• Spokane City Council Passes Aggressive Speeding Ordinance

Cosmos Health reported record quarterly revenue of $17.9 million, representing a 31% increase compared to the prior-year period. The company also continued improving its balance sheet, reducing total liabilities by approximately $4.5 million while increasing stockholders' equity by 7.6%.

Management noted that U.S. expansion initiatives remain actively underway, creating additional opportunities for future growth and market penetration.

Expanding The 18 Series Nutraceutical Platform

A major component of Cosmos Health's growth strategy is the commercialization of its proprietary 18 Series nutraceutical portfolio.

Recent launches include Cur18®, Fort18®, Liv18®, and Oliv18®, products designed to address large and growing wellness categories including inflammation support, cardiovascular health, liver health, immune support, and metabolic wellness.

Management believes these proprietary products offer significantly higher margins than traditional pharmaceutical distribution operations and can become increasingly important contributors to future revenue and earnings growth.

Artificial Intelligence And Research Expansion

Beyond its commercial operations, Cosmos Health continues investing in artificial intelligence initiatives designed to improve efficiency, accelerate product development, and support future healthcare innovation.

The company is integrating AI technologies across multiple business functions while continuing AI-assisted research programs focused on obesity, oncology, inflammatory disorders, and other major healthcare challenges.

Further supporting these efforts, Cosmos Health recently announced an advisory engagement related to a proposed €50 million research and development program that may qualify for up to €25 million in financing through the European Investment Bank Venture Debt Program.

Management believes these initiatives could strengthen the company's innovation pipeline while creating additional long-term growth opportunities.

Proprietary Brands And Telehealth Create Multiple Growth Drivers

Cosmos Health continues expanding a portfolio of proprietary healthcare brands that includes Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept®, C-Scrub®, and the growing 18 Series product family.

These products are expected to contribute a larger percentage of revenue over time while supporting continued margin expansion.

The company also maintains exposure to the growing digital healthcare market through ZipDoctor, Inc., its Texas-based telehealth platform. Management believes telehealth can serve as both a growth driver and future distribution channel for healthcare products and services.

More on Washingtoner

• Traian TKD Tractari Auto Iasi: cum transporti legal la RAR o masina fara numere sau cu ITP expirat
• Republican National Hispanic Assembly & Metropolitan Republican Club Announce Strategic Partnership
• Lake East Landscape Highlights Full-Service Landscaping Solutions Across Seattle and Nearby Areas
• Proactive Tax & Advisory and Accountability Services Merge and Rebrand as Proactive Advisory Group
• Mike Williams Golf Center Now Open at Georgia's Lanier Islands Resort

This combination of telehealth, manufacturing, distribution, nutraceutical development, and proprietary healthcare brands creates a diversified operating model that differentiates Cosmos Health from many healthcare companies of similar size.

Strengthening Financial Foundations

Cosmos Health recently announced the expiration of approximately 4.87 million unexercised Series B warrants.

Management highlighted that the expiration reduces potential future dilution while simplifying the company's capital structure. Combined with ongoing liability reductions and improving shareholder equity, the development further strengthens the company's financial position as it pursues long-term growth objectives.

Positioned For Continued Expansion

As healthcare markets continue evolving globally, Cosmos Health appears increasingly positioned to capitalize on opportunities across nutraceuticals, telehealth, proprietary healthcare products, artificial intelligence-assisted drug development, preventive healthcare, and digital health services.

With record revenue growth, improving financial fundamentals, expanding proprietary product offerings, advancing AI initiatives, growing international distribution, and a long-term roadmap targeting more than $200 million in annual revenue, Cosmos Health continues executing on a strategy designed to build a diversified and scalable global healthcare platform.

Investors seeking exposure to a growing healthcare company with multiple potential growth catalysts may find Cosmos Health increasingly worthy of attention as management pursues what could be its most significant expansion phase to date.

For more information on $COSM visit:  www.cosmoshealthinc.com, www.skypremiumlife.com,   www.cana.gr/en/home/, www.zipdoctor.co,  https://cloudscreen.gr/en/

Media Contact:
Company Name:  Cosmos Health, Inc. (N A S D A Q: COSM),
Contact: BDG Communications
Email:  cosm@bdgcommunications.com  or info@cosmoshold.com
Phone: (312) 865-0026
Country: United States

DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website